Radiolabeled estradiol derivatives to predict response to hormonal treatment in breast cancer: a review.
Several radiolabeled steroidal and nonsteroidal estradiol derivatives of which the tumoral uptake is believed to relate quantitatively to the content and binding characteristics of the alpha-estrogen receptor (alphaER) receptor in the target tissue have been synthesized and their imaging potential and clinical usefulness evaluated in vivo in humans. Due to the use of different methodologies and cut-off values for the measurement of alphaER positivity, the use of both quantitative positron emission tomography and semiquantitative single-photon emission tomography, and the difference in patient populations studied, direct comparison of these data is not possible. Individual data, however, fail to substantiate a direct relationship between these radiolabeled estradiol derivatives and alphaER status, in keeping with recent pathophysiological findings demonstrating (1) estradiol sequestration and retention through other than alphaER-mediated, either membrane- or non-membrane-related, mechanisms and (2) an inverse relationship between estradiol uptake and local biosynthesis through aromatization and interconversion in alphaER-positive tumors. Additionally, given the discovery of very high affinity alphaER-like binding sites (Kd, dissociation constant, <0.1 nM), and the potential for underestimation of aER Kd when using ligand binding assays, at least part of the radiolabeled estradiol derivative uptake reflects tumoral perfusion rather than the ligand-receptor binding process. However, the reduction in cellular uptake, membrane sequestration and local biosynthesis of estradiol following tamoxifen treatment in alphaER-responsive tumors should allow early prediction of response to therapy through rapid sequential radiolabeled estradiol scintigraphy with higher accuracy than conventional alphaER estimations, as supported by recent data.
Van de Wiele
C
C
Division of Nuclear Medicine, University Hospital Ghent, Belgium.
De Vos
F
F
Slegers
G
G
Van Belle
S
S
Dierckx
R A
RA
D001665:Binding Sites; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D004958:Estradiol / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D047628:Estrogen Receptor alpha; D005260:Female; D006801:Humans; D011869:Radioligand Assay; D011960:Receptors, Estrogen / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use*
D020847:Estrogen Receptor Modulators; D047628:Estrogen Receptor alpha; D011960:Receptors, Estrogen; D013629:Tamoxifen; D004958:Estradiol